Sanofi (ENXTPA:SAN) Permanently Halted Its Phase 3 Infant RSV Vaccine Trial

Phase 3negativeInfant RSV VaccineNegative

AI Analysis

Summary

Sanofi has permanently halted its Phase 3 clinical trial for an infant RSV vaccine candidate. The decision represents a significant setback for the company's respiratory vaccine pipeline.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Not Met

Outcome Details

Permanently halted

Importance:7/10

Sentiment:

-0.85

clinical trialPhase 3RSV vaccinetrial haltpediatric

Related Companies

$SNY

Read the original article

Published by yahoo_finance on August 29, 2026 6:10 PM

Read Original